Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 33,719 shares of the company's stock, valued at approximately $2,853,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned about 0.07% of Axsome Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Strategic Financial Concepts LLC acquired a new position in Axsome Therapeutics during the fourth quarter worth approximately $2,599,000. Intech Investment Management LLC grew its position in shares of Axsome Therapeutics by 46.5% in the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock valued at $1,356,000 after purchasing an additional 5,087 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $14,771,000. Charles Schwab Investment Management Inc. grew its position in shares of Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after purchasing an additional 5,438 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $395,000. Institutional investors and hedge funds own 81.49% of the company's stock.

Wall Street Analysts Forecast Growth

AXSM has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price target on the stock. Wells Fargo & Company reissued an "overweight" rating and set a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. Morgan Stanley increased their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Cantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, Bank of America increased their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $172.14.

Axsome Therapeutics Stock Up 0.7%

Shares of NASDAQ:AXSM opened at $108.30 on Tuesday. The firm has a market cap of $5.33 billion, a P/E ratio of -18.08 and a beta of 0.46. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13. The business has a fifty day simple moving average of $110.27 and a 200 day simple moving average of $105.43.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.